NASDAQ:RKDA
Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc.'s revenue fell 3.7% in fiscal 2025 to $4.9M while operating margin rose to −51.5%, its highest in 10 years. Free cash flow was −$4.7M, −97.6% of revenue.Summary generated from Arcadia Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$4.9M
Revenue growth−3.7%
Revenue, 5-yr CAGR−9.6%
Gross margin36.2%
Operating margin−51.5%
Net margin−48.1%
ROICn/a
Return on equity−45.1%
Debt / equityn/a
Free cash flow−$4.7M
FCF margin−97.6%
Share count change+0.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 7 | 7 | 4 | 5 | 5 |
| Operating income | −36 | −14 | −6 | −4 | −3 |
| Net income | −15 | −15 | −14 | −7 | −2 |
| Free cash flow | −27 | −14 | −15 | −10 | −5 |
Recent filings
- 8-KDirector or officer change
Sep 15, 2026 - 4Insider transaction report
Sep 14, 2026 - 4Insider transaction report
Sep 14, 2026 - 8-KNotice of delisting or listing-rule failure
Sep 4, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - DEF 14AProxy statement
Aug 10, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 10, 2026